Престанс

Quick links to important sections

Престанс

Selected form

Treatment option: Angina Pectoris

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Престанс

Property Description
Active ingredient Amlodipine, Perindopril Arginine
Form Oral tablet (Single-pill combination)
Pharmacological class ACE Inhibitor with a Calcium Channel Blocker
Common use Management of high blood pressure
Origin Synthetic pharmaceutical product

Престанс is a synthetic Antihypertensive agent provided as a Prescription-only medicine for cardiovascular management. This medicine is clinically classified as a Fixed-dose combination (FDC) product belonging to the class of ACE Inhibitors with Calcium Channel Blocking Agents. This dual-action structure is designed to simultaneously target two distinct pathways involved in regulating blood pressure, a strategy utilized in managing moderate to severe hypertension.

The active core of the Престанс tablet comprises the Active ingredients Amlodipine and Perindopril Arginine. This formulation is known as a Single-pill combination (SPC), which integrates both the calcium channel blocker and the ACE inhibitor into a single unit. The combination of Perindopril and Amlodipine is designed to provide potent and sustained blood pressure control. This approach utilizes the therapeutic benefits of combining the effects of amlodipine with the systemic inhibition provided by perindopril.

The primary purpose of Престанс is to provide comprehensive and sustained control over high blood pressure, specifically managing conditions such as Essential hypertension in adults. The two components create a Therapeutic synergy that lowers systemic pressure more effectively than relying on either agent alone. Fixed-dose combinations are designed to enhance patient adherence compared to multi-pill regimens. This makes the SPC format particularly relevant for patients requiring long-term, consistent management of their blood pressure, promoting better long-term Cardiovascular risk reduction.

What side effects are possible with Престанс?

The safety profile of Престанс (Amlodipine/Perindopril Arginine) is formally documented in government regulatory sources and categorized by the type and frequency of reported adverse reactions.

Frequency-Classified Adverse Reactions

Adverse effects are grouped into System-Organ Classes (SOCs). Reactions officially classified as Very Common (ge 1/10) include Peripheral edema (swelling). Reactions classified as Common (ge 1/100 to <1/10) include ACE inhibitor-related Cough, Headache, Dizziness, and Fatigue. Some effects, such as dizziness and somnolence, are noted to be more frequently observed especially at the beginning of the treatment.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight serious, high-risk safety concerns, including the potential for Angioedema (swelling of the face, throat, or tongue), a rare but life-threatening event. The medicine is Contraindicated in the second and third trimesters of pregnancy due to the risk of Fetal Toxicity (injury and death to the developing fetus). Other serious reactions documented include Myocardial Infarction and clinically significant events like Hyperkalemia (high potassium levels) and Acute Renal Failure.

Population-Specific Safety Considerations

The medicine is generally not recommended for patients with severe hepatic impairment or severe renal impairment (GFR < 60 mL/min). Official warnings note that African-American patients may experience a higher incidence of ACE inhibitor-related angioedema. Furthermore, the combination is contraindicated with specific medications, notably Neprilysin inhibitors and aliskiren in patients with diabetes, due to substantially increased safety risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the Amlodipine/Perindopril combination is officially characterized by profound hemodynamic manifestations. The primary documented clinical sign is excessive hypotension, a severe decrease in blood pressure that can be life-threatening. Regulatory-listed concerns include a rapid heartbeat and significant metabolic disturbances, specifically clinically significant hyperkalemia (high potassium levels). These effects may lead to serious outcomes, including acute renal failure.

Immediate emergency medical attention is the explicit regulatory mandate following any suspected overdose. Official guidance requires patients to contact a Poison Help line or seek emergency medical attention right away. Emergency services must be contacted immediately (e.g., calling 911) if the person who overdosed experiences severe manifestations such as being collapsed, having a seizure, or being unable to be awakened.

Management is primarily symptomatic and supportive, as no specific antidote is documented in regulatory labeling. Treatment for severe hypotension may include the administration of intravenous sodium chloride 0.9% solution. Regulatory notes specify that the Amlodipine component is not dialyzable due to its high protein binding. Patients with pre-existing renal impairment face an increased risk of severe hyperkalemia and acute renal complications in an overdose situation.

Therapeutic Uses of Престанс

The fixed-dose combination of Amlodipine and Perindopril Arginine supports management across key therapeutic areas of cardiovascular health. This combination is utilized for managing hypertension, helping maintain sustained control, and providing long-term supportive management.

Comprehensive Control and Supportive Management

This medication is commonly used to manage essential hypertension (chronic high blood pressure) in adults. Its therapeutic applications include long-term management of essential hypertension and symptomatic support for individuals with stable coronary artery disease. It helps address symptoms related to heightened physiological activity, such as chronically elevated systemic pressure, by providing dual-action support. This approach is relevant in situations where functional stability becomes affected when using a single agent. The treatment helps address groups of symptoms by supporting consistent, clinically relevant moderation of readings, which assists with maintaining functional stability.

The combination may be part of symptomatic management applied in addressing the long-term risk factors associated with major cardiovascular events. This treatment contributes to easing the overall symptom load related to systemic imbalance in this therapeutic area.

Quick Fact: Management of Chronically Elevated Systemic Pressure

The fixed-dose combination supports the management of conditions characterized by increased physiological stress, assists with maintaining functional stability when symptoms become more noticeable.

Eligibility and Restrictions for Use

The use of Престанс is strictly limited to the adult population and is governed by specific regulatory eligibility criteria. The medicine is contraindicated in several patient groups. These absolute prohibitions include any patient with a history of angioedema, whether hereditary, idiopathic, or related to prior treatment with an ACE inhibitor.

Use is strictly prohibited for women during the second and third trimesters of pregnancy, and it is generally not recommended during breastfeeding. The medication is contraindicated for patients with severe renal impairment (creatinine clearance below 30 mL/min) and those with severe hepatic impairment. The fixed-dose combination is generally deemed not suitable for individuals with moderate renal impairment (creatinine clearance below 60 mL/min).

Престанс is contraindicated if used concomitantly with sacubitril/valsartan and must be avoided with aliskiren in patients diagnosed with diabetes or pre-existing renal impairment. Regarding age, the medicine is not recommended for use in children and adolescents (under 18 years) because safety and efficacy have not been established. It is also not indicated for the initiation of treatment in the older adult population (ge 65 years).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Престанс (Amlodipine/Perindopril) is structured around interaction patterns documented in government sources, primarily addressing the risks associated with its two components.

Officially Contraindicated Combinations

Certain combinations are strictly prohibited due to severe, documented risks. This includes co-administration with Sacubitril/Valsartan, which carries a significant risk of angioedema. Aliskiren is contraindicated in patients with established diabetes or moderate-to-severe renal impairment. Furthermore, agents that elevate potassium levels, such as potassium-sparing diuretics (e.g., Triamterene) and potassium supplements, are contraindicated due to the documented risk of hyperkalaemia caused by the Perindopril component.

Exposure and Pharmacodynamic Effects

Interactions that alter drug exposure are described in official labeling. Strong and moderate CYP3A4 inhibitors are documented to increase the systemic exposure (plasma concentration) of Amlodipine, while CYP3A4 inducers are stated to reduce it. A specific regulatory constraint requires that the dose of Simvastatin must not exceed 20 mg per day when co-administered, due to Amlodipine increasing its exposure.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the intended hypotensive effect and increase the risk of renal function deterioration. Grapefruit or Grapefruit Juice may increase Amlodipine exposure, and co-administration with alcohol may result in an additive hypotensive effect.

Mechanism of Action

How Престанс Works

Престанс functions as a dual-action pharmacological agent, primarily modulating the activity of the Renin-Angiotensin System (RAS) through two distinct, simultaneous pathways. The first pathway involves the specific, non-competitive antagonism of the Angiotensin II Type 1 ( AT1) receptor. By binding to the AT1 receptor, the agent blocks the subsequent intracellular signaling cascade typically mediated by Angiotensin II, which results in the decreased IP3 turnover and reduced Ca^2+ mobilization within vascular smooth muscle cells.

The second pathway entails the parallel inhibition of the Angiotensin-Converting Enzyme ( ACE). This ACE inhibition reduces the conversion of Angiotensin I to the vasoconstrictive Angiotensin II, further diminishing the overall ligand concentration available for AT1 receptor binding. The combined AT1 antagonism and ACE inhibition lead to a systemic physiological consequence: the modulation of vascular tone and a resultant decrease in total peripheral resistance due to balanced vasodilation. This system-level effect is achieved purely through biochemical interaction at the molecular and cellular levels.

Dosage and Administration Information

The use of Престанс (Amlodipine/Perindopril) follows a standard administration protocol for this fixed-dose combination.

Administration Protocol

The medicine is administered by the oral route, taken as a tablet, and is intended for chronic, long-term management. A consistent dosing routine is followed to maintain therapeutic effect.

Feature Administration Guideline
Route of Administration Oral tablet, swallowed whole with water.
Dosing Frequency Once daily.
Optimal Timing Preferably taken in the morning and before a meal.
Preparation The tablet must be swallowed whole; it is not intended for crushing or splitting.

Dosing Regimen and Adjustments

The standard protocol begins with a low fixed-dose strength (e.g., 3.5 mg/2.5 mg) to start therapy. Subsequent dosage adjustments are typically made by the prescriber at intervals of 7 to 14 days based on patient response. The maximum recommended dose is generally 14 mg Perindopril Arginine / 10 mg Amlodipine once daily.

Special Population Rules

Specific considerations exist for certain patient groups. For older adults and individuals with impaired renal or hepatic function, treatment initiation requires careful consideration, and lower starting doses may be necessary. If a dose is missed, the recommended approach is skipping the missed dose and taking the next scheduled dose at the usual time, with a strict prohibition on taking a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Престанс

Evidence for Use in Essential Hypertension

Randomized Controlled Trials (RCTs) represent a key part of the research for this combination. These studies were applied in research contexts involving patients with essential hypertension. Researchers examined the fixed-dose combination (FDC) against single-pill regimens and placebo to understand how symptoms evolved in the observed populations. These studies often focused on outcomes related to physiological strain or stress by monitoring blood pressure.

Research explored changes measured during the study period, primarily documenting measured shifts in both the upper (systolic) and lower (diastolic) blood pressure readings. The trials also monitored how many study participants reached specific blood pressure targets. For some patients, studies also monitored how the treatment was associated with changes in structural markers, such as the size of the heart's left ventricle, over intermediate time intervals. Findings describe patterns observed in the studies that contributed to the broader evidence landscape for fixed-dose regimens in essential hypertension.

Evidence for Use in Stable Coronary Artery Disease

This segment outlines the research exploring how the component regimen was evaluated in individuals with stable coronary artery disease (CAD). The evidence is largely derived from long-term cardiovascular outcomes trials where the component medications were used as a therapeutic strategy. Research examined outcomes reflecting daily functioning or activity level and the incidence of major events. These studies were conducted over extended periods, with some follow-up durations lasting several years.

Long-term research describes the patterns observed in the studies regarding the occurrence of major outcomes, such as non-fatal heart attacks and strokes. Evidence suggests that the use of this therapeutic strategy was studied regarding major cardiovascular events in the observed populations. Research highlights that this combination was examined in the context of the long-term management of conditions involving periods of heightened symptoms and functional limitations.

Key Evidence Gaps and Remaining Research Questions

The research base has also been evaluated in specific patient subgroups, such as older adults and those with diabetes. However, data for certain groups remain insufficient for broad conclusions. Furthermore, comparative evidence is lacking between the specific fixed-dose combination pill and taking the same amount of the two medications as separate tablets. The primary evidence is limited by the fact that dedicated controlled trials using the specific FDC pill to assess major long-term outcomes, such as cardiovascular events, are not well characterized.

Frequently Asked Questions (FAQ)

Common questions about Престанс (FAQ)

Q: How quickly does Престанс start to work?

According to official product information, the initial blood pressure lowering effect from one component may begin within a few hours. However, the full, maximum therapeutic effect of the dual combination is generally reached within one to two weeks of consistent administration. This timeframe is consistent with how the full therapeutic effect is typically assessed.


Q: Is treatment with Престанс usually lifelong?

The medication is officially indicated for chronic, long-term management of conditions like essential hypertension. The decision to discontinue treatment, change the dose, or modify the regimen is one that should be made exclusively by the prescribing physician.


Q: What are the most common side effects reported in official documents?

Based on official frequency data, the most common (Very Common) adverse reaction described is swelling of the ankles or feet (peripheral edema). Other frequently reported (Common) effects include a persistent cough associated with ACE inhibitors, headache, dizziness, and fatigue.


Q: Can Престанс affect mood or sleep?

Official safety documents indicate that this medication may be associated with uncommon side effects related to the nervous system. These documented, non-frequent effects include specific sleep disturbances like insomnia and general changes in mood.


Q: How long should one wait before adjusting the treatment plan?

Official regulatory protocol guides prescribers to evaluate the patient's response and consider dosage adjustments typically no sooner than 7 to 14 days after starting the drug or changing the dose. This interval is specified to allow the medication's effect to stabilize before the prescriber considers adjustments.


Q: Does taking food affect the absorption of Престанс?

Official documents advise taking the medication before a meal in the morning. This specific timing instruction is provided because the presence of food may influence the rate or extent of absorption and overall action of one of the active components.


Q: Is Престанс a heart medicine or a blood pressure medicine?

Престанс is primarily classified as an antihypertensive agent used to manage high blood pressure (essential hypertension). However, official indications also include its use as maintenance therapy for patients with stable coronary artery disease, linking its action to broader cardiovascular health.


Q: How is Престанс different from other blood pressure medications?

The medication is unique in that it is a fixed-dose combination containing two different classes of antihypertensive drugs: an ACE inhibitor and a calcium channel blocker. This dual action is intended to achieve more effective and consistent blood pressure control through simultaneous targeting of two distinct pathways.


Q: Are there side effects that appear later, after prolonged use?

The official safety data notes that some serious, yet rare, adverse events, such as angioedema (swelling of the face or throat), may occur at any point during treatment, including after an extended period of use. Other mild effects like dizziness are often more noticeable when treatment begins.


Q: Can taking Престанс affect blood test results?

Official warnings indicate that the use of this medication may lead to specific changes in laboratory test results. This includes the potential for elevated potassium levels (hyperkalaemia) and increases in creatinine. The official label suggests that these changes may require routine monitoring.


Q: Does Престанс affect the ability to drive?

Official documents contain cautions regarding the ability to operate vehicles and machinery. This is because common side effects, such as headache, fatigue, or dizziness, may temporarily impair attention and reaction time. Official cautionary statements recommend that individuals be aware of their response before operating vehicles or machinery.


Q: Does Престанс affect male sexual function?

The official safety data for the components of the medication describes erectile dysfunction as an an uncommon side effect. This type of effect is noted in the adverse reaction profile of the drug.


Q: Can Престанс interact with supplements or herbal products?

Regulatory documentation notes that specific herbal supplements, such as St. John's wort, may cause significant interactions, potentially reducing drug effectiveness. However, official drug-labeling processes do not typically include formal interaction checks for the majority of over-the-counter dietary supplements.


Q: Is it dangerous to take painkillers while using Престанс?

Taking certain types of over-the-counter painkillers classified as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the drug's blood pressure lowering effect. Official warnings also state that combining these medications increases the risk of deterioration in kidney function.


Q: Why are combination drugs like Престанс prescribed to some people?

Combination products are prescribed because they are documented to achieve more stable and pronounced blood pressure control than single medications. Furthermore, official research indicates that using a single combination pill helps improve patient adherence (consistency of taking the drug).


Q: Is a special diet required while taking Престанс?

Official documents specifically advise patients to avoid the consumption of grapefruit or grapefruit juice due to potential drug interactions. Since one component affects potassium levels, control of salt and potassium intake is a complementary component of hypertension management.


Q: What symptoms indicate that Престанс is not suitable?

Symptoms that require immediate medical attention are those related to serious reactions described in official safety documents. Official safety documents highlight that swelling of the face, lips, or throat (angioedema) is a critical symptom requiring immediate medical attention.


Q: What is the difference between Престанс and taking its components separately?

The main difference is the convenience of taking one single-pill combination (SPC) instead of two separate tablets. Studies indicate this simplicity supports better patient adherence. However, the long-term comparative outcomes between the fixed-dose combination and taking the components separately have not been fully assessed.


Q: Why might I feel dizzy during treatment with Престанс?

Dizziness is classified as a common side effect of the drug. This effect is often linked to the core mechanism of action, where the medication effectively lowers systemic blood pressure and causes the relaxation of blood vessels.


Q: Is there a special formulation of Престанс for children?

Official regulatory guidelines state that the medication is not recommended for use in children and adolescents under 18 years of age. This is because the safety and efficacy of the drug in this specific age group have not been formally established.


Q: What does 'fixed-dose combination' mean for Престанс?

A fixed-dose combination means that the two active ingredients, Amlodipine and Perindopril, are combined into one single tablet in a strictly predetermined ratio. This proportion cannot be changed, ensuring the patient receives both medications simultaneously in a consistent dose.


Q: Does Престанс only lower blood pressure or does it have other functions?

The drug's primary function is to manage high blood pressure (hypertension). It is also officially indicated for use as supportive therapy for individuals diagnosed with stable coronary artery disease.


Q: Why do doctors often prescribe Престанс as a first-line treatment?

The medication is based on a component combination that is proven effective for controlling blood pressure, according to data from randomized controlled trials (RCTs). The strategy of using combination therapy is widely adopted and supported by current guidelines for the management of hypertension.


Q: Is Престанс difficult to obtain without a prescription?

Престанс is classified strictly as a prescription-only medicine. Therefore, it must be obtained by the patient only after receiving an official prescription and authorization from a licensed healthcare provider.


Q: Does Престанс increase the risk of falls in the elderly?

Due to the documented risk of common side effects like dizziness and fatigue, official documents recommend caution when initiating treatment in older adults. Physicians are typically advised to start with lower doses to mitigate potential risks related to balance and falls.


Q: What are the general lifestyle recommendations while taking Престанс?

Official documents focus primarily on the pharmacological treatment and specific dietary warnings, such as avoiding grapefruit juice. General healthy lifestyle practices are often complementary to hypertension treatment, including controlling salt consumption.


Q: What should be done if Престанс causes severe fatigue?

Fatigue (uтомляемость) is officially classified as a common side effect in regulatory documentation. If this symptom is severe or causes significant concern, a consultation with the prescribing specialist is indicated.


Q: Why is it necessary to regularly measure blood pressure while taking Престанс?

Regular blood pressure measurement is necessary so the physician can accurately assess the patient’s response to the treatment. This monitoring is required to determine whether a dose adjustment is needed according to the official dosing protocol.


Q: Is it possible to be allergic to the inactive components of Престанс?

The official contraindications list includes hypersensitivity not only to the active substances but also to any of the excipients (inactive components) used in the formulation of the tablet.


Q: How soon after starting Престанс should laboratory tests be conducted?

Official recommendations often indicate the necessity of monitoring kidney function and blood potassium levels, particularly when starting the treatment or when the dose is changed. This monitoring is often done relatively soon after initiation to check for documented changes.


How should Престанс be stored and disposed of?

How to Store and Dispose of Perindopril and Amlodipine

To ensure product stability, the medication must be stored according to official regulatory labeling. Store the tablets at controlled room temperature, typically between 20 C and 25 C (68 F to 77 F). The product must be protected from both moisture and light, and should not be stored in high-humidity areas, such as a bathroom.

Keep the medicine in its original container and ensure the container is tightly closed to protect the integrity of the tablets. For safety, this and all medicines must be kept out of the sight and reach of children.

Disposal of unused or expired tablets must adhere to federal and local regulations. Do not flush the medication down the toilet unless explicitly instructed by a take-back or regulatory program. Follow official procedures for proper household disposal if a take-back option is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Престанс found in:

A-Z Index: